好_老虎社区_美港股上老虎 - 老虎社区

1
评论
收藏

單單樱花
2021-12-22

好

《新股消息》百心安(02185.HK)公开发售轻微超购及下限定价21.25元一手中签率85%

百心安公布招股结果，每股发售价定为21.25元，为下限定价，香港公开发售部分仅录得超额认购约0.52倍。而国际发售部分亦轻微超购。每手500股计，一手中签率85%，认购2手即1,000股可稳获一手。该股将於明日挂牌。

《新股消息》百心安(02185.HK)公开发售轻微超购及下限定价21.25元一手中签率85%

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

1

举报

评论

推荐
最新

empty

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2024 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":691310939,"tweetId":"691310939","gmtCreate":1640135685119,"gmtModify":1640135685184,"author":{"id":3586582918895260,"idStr":"3586582918895260","authorId":3586582918895260,"authorIdStr":"3586582918895260","name":"單單樱花","avatar":"https://static.tigerbbs.com/fa2d716043d59d15254d5d5ceb84e51f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>好</p></body></html>","htmlText":"<html><head></head><body><p>好</p></body></html>","text":"好","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/691310939","repostId":2193161743,"repostType":4,"repost":{"id":"2193161743","kind":"news","pubTimestamp":1640132660,"share":"https://www.laohu8.com/m/news/2193161743?lang=&edition=full","pubTime":"2021-12-22 08:24","market":"us","language":"zh","title":"《新股消息》百心安(02185.HK)公开发售轻微超购及下限定价21.25元  一手中签率85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2193161743","media":"AAFN","summary":"百心安公布招股结果，每股发售价定为21.25元，为下限定价，香港公开发售部分仅录得超额认购约0.52倍。而国际发售部分亦轻微超购。每手500股计，一手中签率85%，认购2手即1,000股可稳获一手。该股将於明日挂牌。","content":"<html><body><p>百心安(02185.HK)公布招股结果，每股发售价定为21.25元，为下限定价(招股价介乎每股21.25至24.79元)，香港公开发售部分仅录得超额认购约0.52倍。而国际发售部分亦轻微超购。每手500股计，一手中签率85%，认购2手即1,000股可稳获一手。该股将於明日(23日)挂牌。独家保荐人为华泰国际。公司预料，上市净集资约4.42亿元，当中约62%用於正在进行的确认性临床试验、注册备案的筹备事宜以及核心产品Bioheart的计划中商业化上市；约21.3%用於在中国正在进行的随机对照临床试验以及肾神经阻断在研产品第二代Iberis的持续开发；约6.7%用於管线中其他在研产品的研发、进行中临床前研究及已规划的临床试验；余下10%作一般企业及营运资金用途。(na/s)~阿思达克财经新闻网址: www.aastocks.com</p></body></html>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《新股消息》百心安(02185.HK)公开发售轻微超购及下限定价21.25元  一手中签率85%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《新股消息》百心安(02185.HK)公开发售轻微超购及下限定价21.25元  一手中签率85%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 08:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1151123&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>百心安(02185.HK)公布招股结果，每股发售价定为21.25元，为下限定价(招股价介乎每股21.25至24.79元)，香港公开发售部分仅录得超额认购约0.52倍。而国际发售部分亦轻微超购。每手500股计，一手中签率85%，认购2手即1,000股可稳获一手。该股将於明日(23日)挂牌。独家保荐人为华泰国际。公司预料，上市净集资约4.42亿元，当中约62%用於正在进行的确认性临床试验、注册备案的...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1151123&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36","relate_stocks":{"02185":"百心安-B","00388":"香港交易所"},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1151123&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2193161743","content_text":"百心安(02185.HK)公布招股结果，每股发售价定为21.25元，为下限定价(招股价介乎每股21.25至24.79元)，香港公开发售部分仅录得超额认购约0.52倍。而国际发售部分亦轻微超购。每手500股计，一手中签率85%，认购2手即1,000股可稳获一手。该股将於明日(23日)挂牌。独家保荐人为华泰国际。公司预料，上市净集资约4.42亿元，当中约62%用於正在进行的确认性临床试验、注册备案的筹备事宜以及核心产品Bioheart的计划中商业化上市；约21.3%用於在中国正在进行的随机对照临床试验以及肾神经阻断在研产品第二代Iberis的持续开发；约6.7%用於管线中其他在研产品的研发、进行中临床前研究及已规划的临床试验；余下10%作一般企业及营运资金用途。(na/s)~阿思达克财经新闻网址: www.aastocks.com","news_type":1},"isVote":1,"tweetType":1,"viewCount":989,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}